Tuesday, March 15, 2022 1:28:46 PM
Recent REVB News
- Revelation Biosciences, Inc. Announces Financial Results for the Three Months Ended March 31, 2024 • Business Wire • 05/10/2024 08:52:00 PM
- Revelation Biosciences, Inc. Announces Financial Results for the Three and Twelve Months Ended December 31, 2023 • Business Wire • 03/22/2024 08:15:00 PM
- Revelation Biosciences Inc. Gives Oral Presentation at Advances in Critical Care Nephrology (AKI & CRRT 2024) • Business Wire • 03/13/2024 01:00:00 PM
- Revelation Biosciences Inc. to Participate in a Virtual Fireside Chat at the 36th Annual Roth Conference • Business Wire • 03/12/2024 01:00:00 PM
- Revelation Biosciences Inc. Announces Commencement of First in Human Phase 1 Clinical Study of Gemini • Business Wire • 03/04/2024 02:00:00 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 01:12:05 AM
- Revelation Biosciences Inc. Receives Invitation to Give an Oral Presentation at The 29th International Conference on Advances in Critical Care Nephrology (AKI & CRRT 2024) • Business Wire • 02/13/2024 02:00:00 PM
- Form SCHEDULE 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/12/2024 03:19:46 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/08/2024 09:01:23 PM
- Revelation Biosciences Inc. Announces Closing of $6.2 Million Public Offering • Business Wire • 02/05/2024 09:41:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 02/02/2024 09:06:10 PM
- Revelation Biosciences Inc. Announces Pricing of $6.2 Million Public Offering • Business Wire • 02/01/2024 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/30/2024 10:21:32 PM
- Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 01/30/2024 08:32:42 PM
- Revelation Biosciences Inc. to Present at The International Conference on Advances in Critical Care Nephrology (AKI & CRRT 2024) • Business Wire • 01/30/2024 02:00:00 PM
- Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 01/29/2024 10:32:32 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/23/2024 09:18:01 PM
- Revelation Biosciences Inc. Announces 1-for-30 Reverse Stock Split Effective January 25, 2024 • Business Wire • 01/23/2024 02:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/22/2024 09:01:09 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 12/22/2023 10:06:53 PM
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 12/22/2023 06:23:34 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 12/12/2023 09:59:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/13/2023 09:30:16 PM
- Revelation Biosciences, Inc. Announces Financial Results for the Three and Nine Months Ended September 30, 2023 • Business Wire • 11/13/2023 09:05:00 PM
Mushrooms Inc. (OTC: MSRM) Announces Significant Share Buy Back by the Board Director and New Strategic Initiatives. • MSRM • Jun 5, 2024 1:32 PM
Hydromer Announces Launch of HydroThrombX Medical Device Coating Technology • HYDI • Jun 5, 2024 10:24 AM
Dr. Michael Dent Finances $1 Million to Drive HealthLynked's Healthcare Transformation • HLYK • Jun 5, 2024 8:00 AM
Avant Technologies Enters Binding LOI to Purchase Dozens of High-Performance, Immersible, AI-Powered Servers • AVAI • Jun 5, 2024 8:00 AM
IQST - iQSTEL Announces $290 Million 2024 Annual Revenue Forecast • IQST • Jun 4, 2024 1:43 PM
ECGI Holdings Accelerates Strategic Initiatives by Securing First of Two $125,000 Convertible Notes • ECGI • Jun 4, 2024 12:15 PM